简介：ThetalentistheenginefactorforShanghaiwhiletransformingtheeconomicdevelopmentmodelinthe12the-five-year-planperiod.TodaythetalentdevelopmentstrategyinShanghaiisnotonlyfacingthegreatchallengesfrominternationalmetropolisanddomesticcities,butalsoexistsaseriesofstructuralproblemsforitself.Toacquireandmaintainitscompetitiveadvantagesinaneraofglobalbrainbattleinfuture,Shanghaineedstodefinitelyorientitsmissiontowardsaglobaltalenthub,acceleratethepaceoftalentsinternationalization,strengthentheadjustmentefforttotalentstructures,enforcethemarketallocationmechanism,optimizethetalentecosystemandinnovatethesystemandmechanism.

简介：第五届拉丁格莱美大奖在美国城市洛杉矶揭晓,来自100多个国家特别是西班牙、葡萄牙的歌手汇聚在洛杉矶世纪广场,欢庆这个属于拉丁歌手的节日。西班牙歌手阿莱德罗·桑茨获得年度最佳专辑等四项大奖,成为此次颁奖典礼上的最大赢家。上届拉丁格莱美“最佳新人”奖的获得者大卫·比斯巴尔与美国流行女歌手杰西卡·辛普森首度合作,len为整场颁奖典礼带来第一首开场曲。WhenthelightscomeuponWednesdaysLatinGrammys,manymu-sicianslikeMexicanbandCafeTacuba,whoarelittleknownintheUnit-edStates,willcompetefortophonoursinashiningHollywoodcomingoutpartyfornewartists.Inashiftfromearlieryears,whenbigmainstreamsuperstarslikeRickyMartinsweptthetopcategories(项目),thefi...

简介：ＰＬＡＮＴＩＮＧ“ＴＡＬＥＮＴＴＲＥＥＳ”ＩＮＶＯＧＵＥＩＮＹＵＮＴＡＩＶＩＬＬＡＧＥ￥／／Ｉｎｒｅｃｅｎｔｙｅａｒｓ，ｍａｎｙｐｅａｓａｎｔｓｉｎｔｈｅｖｉｌｌａｇｅｏｆＹｕｎｔａｉｉｎＨｕｎａｎｐｒｏｖｉｎｃｅｈａｖｅｍａｄｅａｌｏｎｇ－ｔｅｒｍ...

简介：

简介：

简介：

简介：AsreportedbyChinaNewsNetwork,aplanwithabeautifulnameforimportingoverseastalentedexperts,TalentPeacockPlan,willascertainadequatehumanresourcesandpromoteindependentinnovationcapabilityofShenzhenwithintheGuangdongProvinceduringthe12thFive-YearPlan.TalentPeacockPlanisoneofthemeansthatShenzhenattemptstosetupthehugeinnovativeteamoftalents.ItisreportedthatShenzhenwillinsistonimporting,developingandgatheringinternationalinnovativehumanresourcestoestablishasuitableandadequatecityfor

简介：你的人力资本管理（HCM）系统是否是最新版本？是否需要升级？人才供求的全球化是商业圈内最具影响力的趋势之一，甚至已经完全改变了企业招贤纳士的方式。新的挑战总是带来新的机遇，企业可以主动应对全球化，使其成为自身优势。然而，为了做到这一点，企业必须确保员工与更广泛的全球化战略是统一战线的。

简介：

简介：

简介：

简介：

简介：摘要：当前，高职院校的教育目标是为社会培养出高素质的应用型专业人才，除了注重学生理论知识的提升，更重要的是锻炼学生动手实操能力。而科学技术的不断深入发展，使得社会及企业对于人才的要求不断提高，由此，高职院校将“1+X”证书制度作为主要人才教育方式。基于此，本文从“1+X”证书制度含义入手，并分析高职院校实施“1+X”证书制度的意义，探析“1+X”证书制度的实施现状，最后重点阐述“1+X”证书制度的培养新模式，以期提升高职院校教育质量，带动学生的竞争力的迅速提升。

简介：AbstractBackground:Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs.Methods:We carried out a 48-week, randomized, controlled, open-label non-inferiority trial at 12 sites in China. Adults on the World Health Organization (WHO)-recommended first-line treatment for >6 months with a plasma viral load >1000 copies/mL were enrolled and randomly assigned (1:1) to receive albuvirtide (once weekly) plus ritonavir-boosted lopinavir (ABT group) or the WHO-recommended second-line treatment (NRTI group). The primary endpoint was the proportion of patients with a plasma viral load below 50 copies/mL at 48 weeks. Non-inferiority was prespecified with a margin of 12%.Results:At the time of analysis, week 24 data were available for 83 and 92 patients, and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups, respectively. At 48 weeks, 80.4% of patients in the ABT group and 66.0% of those in the NRTI group had HIV-1 RNA levels below 50 copies/mL, meeting the criteria for non-inferiority. For the per-protocol population, the superiority of albuvirtide over NRTI was demonstrated. The frequency of grade 3 to 4 adverse events was similar in the two groups; the most common adverse events were diarrhea, upper respiratory tract infections, and grade 3 to 4 increases in triglyceride concentration. Renal function was significantly more impaired at 12 weeks in the patients of the NRTI group who received tenofovir disoproxil fumarate than in those of the ABT group.Conclusions:The TALENT study is the first phase 3 trial of an injectable long-acting HIV drug. This interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure.Trial registration:ClinicalTrials.gov Identifier: NCT02369965; https://www.clinicaltrials.gov.Chinese Clinical Trial Registry No. ChiCTR-TRC-14004276; http://www.chictr.org.cn/enindex.aspx